U.S. market Closed. Opens in 2 days 6 hours 24 minutes

CRSP | CRISPR Therapeutics AG Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Revenue370.00M436.00K913.08M543.00K289.59M3.12M41.00M5.16M247.00KN/A
Cost of Revenue130.25M110.25M17.95M269.41M179.36MN/AN/AN/AN/AN/A
Gross Profit239.75M-109.81M895.13M-268.86M110.23M3.12MN/AN/AN/AN/A
Operating Expenses462.29M563.35M539.55M354.98M242.85M162.07M105.64M73.29M25.98MN/A
Selling, General & Admin76.16M102.46M102.80M88.21M63.49M48.29M35.84M31.06M13.40M5.11M
Research & Development387.33M461.64M438.63M266.95M179.36M113.77M69.80M42.24M12.57M1.51M
Other Operating Expenses71.82M-762.00K-1.88M-176.00K20.57M-5.49MN/AN/AN/AN/A
Operating Income-222.54M-673.16M373.53M-354.44M46.74M-158.94M-64.65M-68.13M-25.73M-6.63M
Other Expenses / Income71.82M22.66M6.00M6.38M20.57M-5.49M-1.96M45.41M-92.00K-236.00K
Before Tax Income-150.72M-650.50M379.53M-348.06M67.31M-164.43M-66.61M-22.72M-25.82M-6.86M
Income Tax Expenses2.89M-325.00K1.87M809.00K448.00K553.00K1.75M484.00K7.00K-63.00K
Net Income-153.61M-650.17M377.66M-348.87M66.86M-164.98M-68.36M-23.20M-25.83M-6.80M
Interest ExpensesN/A-46.83MN/AN/AN/AN/AN/A8.05M108.00KN/A
Basic Shares Outstanding79.22M77.75M75.95M65.95M54.39M47.96M40.06M12.26M20.24M29.30M
Diluted Shares Outstanding79.22M77.75M80.39M65.95M56.93M47.96M40.06M12.26M20.24M29.30M
EBITDA-202.70M-673.16M373.53M-345.25M46.74M-158.94M-63.58M-13.74M-25.59M-6.83M
EBITDA Margin-54.78%-154,394.72%40.91%-63,582.14%16.14%-5,087.80%-155.09%-266.13%-10,358.70%0.00%
EBIT-150.72M-697.33M379.53M-348.06M67.31M-164.43M-66.61M-14.67M-25.71M-6.86M
EBIT Margin-40.74%-159,938.76%41.57%-64,098.71%23.24%-5,263.38%-162.47%-284.04%-10,410.12%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙